Post covid 19 pulmonary fibrosis. Is it real threat?

Indian J Tuberc. 2021 Jul;68(3):330-333. doi: 10.1016/j.ijtb.2020.11.003. Epub 2020 Nov 10.

Abstract

After the COVID-19 outbreak, increasing number of patients worldwide who have survived COVID-19 continue to battle the symptoms of the illness, long after they have been clinically tested negative for the disease. As we battle through this pandemic, the challenging part is to manage COVID-19 sequelae which may vary from fatigue and body aches to lung fibrosis. This review addresses underlying mechanism, risk factors, course of disease and treatment option for post covid pulmonary fibrosis. Elderly patient who require ICU care and mechanical ventilation are at the highest risk to develop lung fibrosis. Currently, no fully proven options are available for the treatment of post inflammatory COVID 19 pulmonary fibrosis.

Keywords: ARDS; Antifibrotic; Covid 19; Pulmonary fibrosis.

Publication types

  • Review

MeSH terms

  • COVID-19 / complications*
  • COVID-19 / epidemiology
  • COVID-19 / therapy
  • Humans
  • Patient Care Management*
  • Pulmonary Fibrosis* / epidemiology
  • Pulmonary Fibrosis* / etiology
  • Pulmonary Fibrosis* / therapy
  • Risk Factors
  • SARS-CoV-2

Supplementary concepts

  • post-acute COVID-19 syndrome